Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis

Authors

  • A. K. Singal,

    1. Division of Gastroenterology, Department of Internal medicine, University of TX Medical Branch, Galveston, TX, USA
    Search for more papers by this author
  • R. J. Fontana

    Corresponding author
    1. Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
    • Division of Gastroenterology, Department of Internal medicine, University of TX Medical Branch, Galveston, TX, USA
    Search for more papers by this author

Correspondence to:

Prof. R. J. Fontana, 3912 Taubman Health Care Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0362, USA.

E-mail: rfontana@med.umich.edu

Summary

Background

The optimal oral anti-viral agent to use in patients with decompensated HBV cirrhosis remains unclear.

Aim

We performed a meta-analysis of the oral nucleos(t)ide analogues in patients with decompensated HBV cirrhosis.

Methods

One year efficacy and safety outcomes in 22 studies published in English between95 and 2010 were analysed.

Results

Substantial heterogeneity was noted in the inclusion/exclusion criteria, controls, and sensitivity of the HBV DNA assay used. Pooled 1-year data showed benefit favouring lamivudine (LAM) vs. untreated controls for Child-Turcotte-Pugh (CTP) score improvement by ≥2 (OR: 117 (15 921), P ≤ 0.0001) and transplant-free survival (OR: 3.2 (1.2, 9), P = 0.022). Adefovir (ADV) led to undetectable HBV DNA at 1-year in 41% compared to 83% with LAM and 80% with entecavir (ETV). Overall, 1-year transplant-free survival rates varied from 78% with LAM to 95% and 94% with Tenofovir (TDF) and Telbivudine (TBV), respectively. The 1-year incidence of drug resistant HBV was 0% with ADV, ETV and TDF and 11% with LAM although TBV was associated with a 29% incidence at 2 years. Drug-related adverse events were infrequently reported.

Conclusions

All the oral anti-viral agents were associated with improved virological, biochemical and clinical parameters at 1-year. However, the efficacy of lamivudine and telbivudine is limited by drug resistance, and adefovir is limited by its potency and slower onset of action. Additional studies of tenofovir and entecavir are needed to determine the optimal agent(s) for treatment naïve patients and in those with drug-resistant decompensated HBV cirrhosis.

Ancillary